Antifungal Drugs Market Size & Share 2026-2035

Antifungal Drugs Market Size

The global antifungal drugs market was valued at approximately USD 16.8 billion in 2025. The market is expected to grow from USD 17.7 billion in 2026 to USD 25.5 billion by 2035, growing at a CAGR of 4.1% during the forecast period, according to the latest report published by Global Market Insights Inc.

The market is growing primarily due to the rising prevalence of fungal infections, increasing immunocompromised patient populations, growing incidence of hospital-acquired fungal infections, and rising awareness regarding early diagnosis and treatment of invasive mycoses.

According to the Centers for Disease Control and Prevention (CDC), fungal diseases such as candidiasis, aspergillosis, cryptococcosis, and mucormycosis continue to pose major healthcare challenges globally, particularly among patients with cancer, HIV/AIDS, organ transplants, and chronic respiratory diseases. For instance, globally, fungal infections affect over 1 billion people annually, causing 3.8 million deaths, underscoring the need for better diagnosis and treatment. Recent studies estimate that 6.5 million people worldwide are affected annually by invasive fungal infections.

In addition, the emergence of multidrug-resistant fungal pathogens such as Candida auris has intensified concerns surrounding antifungal resistance and treatment limitations. As per the International Society for Infectious Diseases (ISID), candida infections claim nearly 1 million lives annually, affecting 1.57 million people worldwide, with a staggering 63.6% mortality rate. Such high disease prevalence increases the demand for effective treatments, thus fostering the market growth.

The antifungal drugs market includes the treatment and management of superficial, systemic, and invasive fungal infections through major drug classes including azoles, echinocandins, polyenes, allylamines, and antimetabolites. These drugs are used to treat a wide range of fungal infections, including superficial infections like athlete's foot, ringworm treatment, and vaginal yeast infections, as well as systemic infections like invasive candidiasis and aspergillosis.

Key players operating in the market include Pfizer, Astellas Pharma, Merck, GSK plc, and Basilea Pharmaceutica Ltd. These companies strengthen their market presence through novel antifungal drug development, strategic collaborations, expansion into resistant fungal infection therapies, and investments in next-generation broad-spectrum antifungal agents.

The market witnessed steady growth between 2022 and 2024, growing from USD 14 billion in 2022 to USD 15.9 billion in 2024. This growth can be attributed to the increasing hospitalization rates, rising prevalence of opportunistic fungal infections, and growing adoption of advanced antifungal therapies in intensive care settings. Increased utilization of prophylactic antifungal therapies among immunosuppressed patients has further aided in the market growth.

Antifungal Drugs Market Trends

• The increasing burden of drug-resistant fungal pathogens is significantly reshaping the market landscape. Candida auris, one of the most concerning multidrug-resistant fungi, continues to spread rapidly across healthcare settings globally.
• According to the Centers for Disease Control and Prevention (CDC), the U.S. reported 6,304 clinical Candida auris cases in 2024, compared to 4,514 cases in 2023 and 1,471 cases in 2021, highlighting the rapid expansion of resistant fungal infections. The emergence of resistant Aspergillus fumigatus and echinocandin-resistant Candida species is further increasing demand for novel antifungal therapeutics.
• The market is also witnessing strong momentum in antifungal research and development following rising global public health concerns surrounding invasive fungal diseases. In 2022, the World Health Organization published its first-ever fungal priority pathogens list, identifying critical fungal threats including Candida auris, Aspergillus fumigatus, Candida albicans, and Cryptococcus neoformans. The initiative aims to accelerate global research, surveillance, and antifungal drug innovation.
• Another important trend is the increasing focus on hospital antifungal stewardship programs and infection prevention strategies. Hospitals are strengthening surveillance and antimicrobial stewardship initiatives to reduce inappropriate antifungal usage and control healthcare-associated fungal outbreaks. Growing awareness regarding fungal co-infections among critically ill patients, cancer patients, and transplant recipients is further supporting demand for systemic antifungal therapies.
• Pharmaceutical companies are increasingly investing in novel antifungal pipelines targeting resistant fungal pathogens and underserved invasive mycoses. Several late-stage antifungal candidates with novel mechanisms of action are being developed to address limitations associated with existing therapies, particularly for multidrug-resistant fungal infections and immunocompromised patient populations.
• For instance, Basilea Pharmaceutica has initiated a Phase 3 study (FORWARD-IM) to evaluate fosmanogepix, a first-in-class, broad-spectrum antifungal for treating invasive mold infections, including Aspergillus spp. and Fusarium spp. The study investigates both IV and oral formulations as primary or salvage therapies for high-risk patients with limited treatment options.
• Overall, the market is rapidly evolving owing to the rising healthcare awareness, increasing hospitalization rates, expanding immunocompromised populations, and growing global surveillance initiatives for fungal pathogens, which are expected to support sustained long-term market growth globally.

Antifungal Drugs Market Analysis

Based on drug class, the market is classified into azoles, echinocandins, polyenes, allylamines, and other drug classes. The azoles segment dominated the market in 2025 with a revenue of USD 8.1 billion due to their broad antifungal spectrum and wide application throughout the clinical community, as well as their availability in both oral and topical formulations.

• Azole antifungal drugs, including fluconazole, voriconazole, itraconazole, posaconazole, and ketoconazole, are frequently used as the first-line therapies for many fungal diseases such as candidiasis, aspergillosis, dermatophytosis, and cryptococcosis.
• Their dominance is further supported by strong physician familiarity, good oral bioavailability, and widespread adoption in hospital and outpatient settings, as well as for prophylactic treatment against fungal infections.
• The segment also benefits from the availability of generic formulations, improving treatment accessibility and supporting high prescription volumes across developed and emerging healthcare markets.
• Additionally, widespread availability of azoles in various formulations, including oral tablets, capsules, creams, and solutions, increases the adoption of these drugs, thereby boosting the market share of this segment.

Based on indication, the antifungal drugs market is segmented into candidiasis, aspergillosis, dermatophytosis, mucormycosis, and other indications. The candidiasis segment dominated the market in 2025 with a market share of 41.2%.

• Candidiasis, caused by Candida species, is one of the most common fungal infections globally. For instance, according to the Centers of Disease Control and Prevention (CDC), in 2021, candidiasis caused around 1,769 deaths in the U.S.
• Additionally, the increasing prevalence and severity of these diseases have increased awareness about the diagnosis and treatment of these diseases. Hence, the demand for antifungal drugs for treating candidiasis has increased, reinforcing the dominance of this segment in the market.
• Furthermore, the treatment of candidiasis benefits from the availability of a wide range of antifungal drug classes such as azoles (e.g., fluconazole, voriconazole), echinocandins (e.g., caspofungin, micafungin), and polyenes, thereby contributing to the growth of this segment.
• The aspergillosis segment held the second-largest market share of 22.4% in the market, mainly fueled by the increasing incidence of invasive aspergillosis cases in immunosuppressed individuals, especially those on chemotherapy, organ transplants, and prolonged corticosteroid treatments.
• Rising incidences of chronic respiratory disorders and hospital admissions have additionally led to an increase in the number of Aspergillus infections worldwide.

Based on infection type, the antifungal drugs market is divided into systemic antifungal infections and superficial antifungal infections. The systemic antifungal infections segment held the majority market share in 2025 and is predicted to grow at a CAGR of 4.8% over the analysis period.

• Increasing incidence of serious fungal infections is a major factor contributing to the dominance of systemic fungal infections.
• In addition, a rise in the number of immunocompromised populations, including cancer patients, transplant recipients, ICU patients, and individuals living with HIV/AIDS, further increases the incidence of invasive fungal infections.
• Systemic fungal infections such as invasive candidiasis, aspergillosis, cryptococcosis, and mucormycosis require long term hospitalization and advanced antifungal therapies, resulting in higher treatment costs and greater market contribution.
• In addition, the increasing adoption of broad-spectrum antifungal agents in hospital settings continues to strengthen the market position of systemic antifungal infection treatments globally.

Based on route of administration, the antifungal drugs market is categorized into oral, topical, and injectable. The oral segment held a high market share in 2025 and is anticipated to reach USD 12.1 billion by the end of forecast timeframe.

• Oral antifungals are popular due to their convenience of use, affordability, and ability to take over an extended period of time.
• Patients can self-administer oral formulations without the need for assistance, thus improving treatment adherence rates and overall patient compliance.
• In addition, the widespread availability of generic oral antifungal agents such as fluconazole and itraconazole further enhances affordability and accessibility across developed and emerging markets.
• Other factors such as favorable oral bioavailability, broad-spectrum antifungal activity, and growing utilization in prophylactic antifungal therapy among immunocompromised populations, continue to support the dominance of oral antifungal formulations in the global market.

Based on medication, the antifungal drugs market is segmented into prescription and OTC. The prescription segment dominated the market and is expected to showcase lucrative growth at 3.5%.

• The dominance of the segment can be attributed to the rising clinical burden associated with severe fungal infections that necessitate potent prescription medication.
• Moreover, due to the rising incidence of resistant strains of antifungal agents, doctors are increasingly relying on prescription-grade antifungals that require precise dosages to be administered under close supervision.
• Adoption of combination antifungals and newer-generation antifungals, such as triazoles and echinocandins, has also contributed to the growth of this segment.
• Prescribed antifungals are also experiencing increasing uptake as prophylactic treatment to prevent opportunistic fungal infections in oncology, hematology, and transplantation medicine.
• Additionally, increasing investments in the hospital sector, improvements in reimbursement, and the availability of novel brands of antifungal drugs are contributing significantly to the dominance of this segment.

Based on type the antifungal drugs market is categorized into branded and generic. Branded segment held notable market share of 58.7% in 2025.

• Branded antifungal medications often benefit from extensive research and development investments made by pharmaceutical companies to discover and develop innovative therapies. These branded drugs typically undergo rigorous clinical trials to demonstrate their safety, efficacy, and superiority over existing treatments, leading to their approval by regulatory authorities.
• This strong scientific evidence supporting branded antifungal drugs enhances their credibility among healthcare providers, leading to increased prescription of branded antifungal drugs, which further contributes to the growth of this segment.

Based on the distribution channel, the antifungal drugs market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment dominated the market and was valued at USD 7.7 billion in 2025.

• High utilization of antifungal therapies in hospital inpatient and critical care settings for the treatment of severe and invasive fungal infections is a major factor driving the demand for antifungal drug in hospital settings.
• Hospitals are the primary point of care for patients suffering from severe fungal diseases such as invasive candidiasis, aspergillosis, cryptococcosis, and mucormycosis, which often require immediate diagnosis, intravenous drug administration, and continuous clinical monitoring.
• Further, the growing number of immunocompromised patients, including cancer patients, organ transplant recipients, ICU patients, and individuals undergoing immunosuppressive therapies, has significantly increased the demand for hospital-based antifungal drugs.
• Furthermore, streamlined procurement and distribution processes within hospital pharmacies facilitate timely access to oral, topical, and intravenous formulations, supporting efficient medication management workflows and growth of the segment.

North America Antifungal Drugs Market

The North America market dominated the global market with a market share of 38.6% in 2025.

• The dominance of North America in the market is attributed to several factors, including the region's highly developed healthcare system, high rates of diagnoses and treatments, and the involvement of leading pharmaceutical companies in the research and production of antifungal drugs.
• Further, North America experiences high incidences of fungal infections among immunocompromised individuals, older people, cancer patients, and transplant patients, thereby driving the demand for antifungal drugs in the region.
• For instance, approximately 1.8% of Canada's population suffers from serious fungal infections, affecting 498,688 individuals. Similarly, an estimated 3,000 invasive fungal infections occur annually, with 2,068 cases of invasive candidiasis.

The U.S. antifungal drugs market was valued at USD 5 billion and USD 5.3 billion in 2022 and 2023, respectively. The market size reached USD 5.9 billion in 2025, growing from USD 5.6 billion in 2024.

• The U.S. market is primarily driven by the increasing burden of invasive fungal infections among immunocompromised patient populations, including cancer patients, organ transplant recipients, and ICU patients.
• According to the Centers for Disease Control and Prevention (CDC), more than 75,000 hospitalizations and nearly 9 million outpatient visits occur every year for fungal diseases in the U.S., contributing significantly to antifungal drug demand.
• The country is also witnessing rapid growth in antifungal resistance, particularly involving Candida auris and azole-resistant Aspergillus fumigatus, increasing demand for next-generation antifungal therapies.
• Furthermore, the presence of major pharmaceutical companies, strong clinical research activity, and growing antifungal drug pipeline development continue to support market expansion in the U.S.

Europe Antifungal Drugs Market

Europe market accounted for USD 4.3 billion in 2025 and is anticipated to show steady growth over the forecast period.

• Europe market growth is supported by the increasing incidence of fungal infections in the region. The burden is further increased due to the ageing population, who are more susceptible to such infections.
• According to the European Commission, individuals aged 65 years and above account for more than 21% of the total European population, increasing vulnerability to opportunistic fungal infections. Further, studies estimate that more than 38 million European individuals are affected by a fungal skin infection, commonly rising among individuals over 60.
• The region also benefits from strong infectious disease surveillance systems, favorable healthcare reimbursement structures, and increasing investments in antimicrobial resistance management programs.

Germany dominates the Europe antifungal drugs market, showcasing strong growth potential.

• Germany holds a strong position in the Europe market due to its advanced healthcare infrastructure, strong pharmaceutical manufacturing base, and high awareness regarding fungal infection diagnosis and treatment.
• High incidence of fungal infections in the country further increases the demand for antifungal drugs. For instance, as per the National Institute of Health (NIH), about 9.6 million (12%) people in Germany suffer from a fungal infection each year.
• In addition, the country benefits from a large immunocompromised population, including elderly patients, cancer patients, and transplant recipients, which has significantly increased the demand for systemic and topical antifungal therapies.

Asia Pacific Antifungal Drugs Market

China market is estimated to grow with a significant CAGR in the Asia Pacific market.

• The market is supported by a large patient population, increasing healthcare expenditure, and expanding access to advanced infectious disease diagnostics and treatment.
• Rapid urbanization, rising prevalence of immunocompromised populations, and increasing incidence of healthcare-associated fungal infections are further supporting market demand.
• In addition, government initiatives aimed at strengthening infectious disease management and hospital infrastructure development are expected to support long-term market growth in China.

Latin America Antifungal Drugs Market

Brazil leads the Latin American market, exhibiting strong growth during the analysis period.

• The market growth is driven by increasing awareness regarding fungal infections, improving healthcare access, and rising incidence of opportunistic fungal diseases among diabetic and immunocompromised populations.
• Expansion of tertiary care hospitals and growing availability of prescription antifungal therapies are further supporting greater treatment adoption across the country.

Middle East and Africa Antifungal Drugs Market

Saudi Arabia market is expected to experience substantial growth in the Middle East and Africa market.

• The market growth is supported by rising healthcare expenditure, increasing hospital infrastructure investments, and growing awareness regarding invasive fungal infections in high-risk patient populations.
• Increasing prevalence of diabetes, cancer, and ICU-related fungal infections is contributing to rising demand for systemic antifungal therapies across the country.
• In addition, advancements in healthcare facilities and expanding access to improved healthcare are expected to improve fungal disease diagnosis and treatment rates.

Antifungal Drugs Market Share

The global market is fragmented in nature, with several multinational pharmaceutical companies and generic players accounting for a substantial share of total market revenue. Major players such as Pfizer, Astellas Pharma, Merck, GSK, and Basilea Pharmaceutica collectively account for ~ 68% share of the global market, supported by extensive antifungal product portfolios, strong hospital distribution networks, and continued investment in infectious disease therapeutics. These companies maintain their market presence through broad-spectrum antifungal offerings, strategic partnerships, strong regulatory approvals, and ongoing development of therapies targeting resistant fungal pathogens.

Companies operating in the market are increasingly focusing on novel antifungal drug development, clinical pipeline expansion, and collaborations aimed at addressing the growing threat of antifungal resistance. Rising incidence of multidrug-resistant fungal infections, particularly involving Candida auris and resistant Aspergillus species, is accelerating investments in next-generation antifungal agents with unique mechanisms of action and improved safety profiles. In addition, pharmaceutical companies are expanding research efforts toward advanced antifungal formulations, combination therapies, and hospital-focused treatment solutions to strengthen their competitive position.

Antifungal Drugs Market Companies

Prominent players operating in the antifungal drugs industry are as mentioned below:

• Astellas Pharma
• Bayer AG
• Cipla
• Gilead Sciences
• Glenmark Pharmaceuticals
• GlaxoSmithKline
• Hikma Pharmaceuticals
• Merck & Co.
• Novartis AG
• Pfizer
• Scynexis
• Sun Pharmaceutical Industries
• Sanofi

• Pfizer

Pfizer has maintained a strong position in the market through widely used therapies such as Diflucan (fluconazole) and Eraxis (anidulafungin), which are used in the treatment of invasive fungal infections including candidiasis. The company benefits from its extensive global hospital network and anti-infectives portfolio, supporting strong penetration in both developed and emerging markets.

• Astellas Pharma

Astellas Pharma is a notable player in the market, primarily driven by its antifungal therapy Mycamine (micafungin), an echinocandin used for the treatment of invasive candidiasis, candidemia, and aspergillosis. The company has a strong presence in hospital-based anti-infective therapies, particularly in North America, Europe, and Asia-Pacific.

Antifungal Drugs Industry News:

• In August 2024, Glenmark Pharmaceuticals launched micafungin for injection in the U.S. market, enabling the company to expand its systemic antifungal portfolio and address invasive fungal infections in hospital settings following regulatory approval.
• In September 2024, the European Medicines Agency reaffirmed authorization of VFEND (voriconazole) for treating invasive aspergillosis and serious fungal infections across Europe, supporting continued clinical utilization of Pfizer’s systemic antifungal therapy.
• In December 2023, Astellas Pharma announced the U.S. FDA approval of CRESEMBA, an azole antifungal drug for treating invasive aspergillosis (IA) and invasive mucormycosis (IM) in pediatric patients. This FDA approval helped the company to diversify its product portfolio and boost its revenue.
• In January 2023, Sandoz signed an agreement with Astella to acquire worldwide product rights for the leading systemic antifungal agent Mycamine. This strategic move helped the company to expand its product portfolio, increase market access, and generate revenue.

The antifungal drugs market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2022 - 2035 for the following segments:

Click here to Buy Section of this Report

Market, By Drug Class

• Azoles
• Echinocandins
• Polyenes
• Allylamines
• Other drug classes

Market, By Indication

• Dermatophytosis
• Aspergillosis
• Candidiasis
• Mucormycosis
• Other indications

Market, By Infection Type

• Systemic antifungal infections
• Superficial antifungal infections

Market, By Route of Administration

• Oral
• Topical
• Injectable

Market, By Medication

• Prescription
• OTC

Market, By Type

• Branded
• Generic

Market, By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE